REGN5093

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

MET-altered non-small cell lung cancer (NSCLC)NSCLC

Phase 1

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

Active, not recruitingNCT04077099

Regeneron PharmaceuticalsNSCLC

Start: 2020-01-07End: 2027-07-06Updated: 2026-09-16

A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER

CompletedCTIS2023-506248-18-00

Regeneron Pharmaceuticals Inc.MET-altered non-small cell lung cancer (NSCLC)

Start: 2020-01-07End: 2025-03-04Target: 35Updated: 2024-06-14

Related Papers

A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-208 citations